Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.76 USD | -2.60% | -5.90% | +35.60% |
Financials (USD)
Sales 2024 * | 69.71M | Sales 2025 * | 72.54M | Capitalization | 277M |
---|---|---|---|---|---|
Net income 2024 * | -125M | Net income 2025 * | -117M | EV / Sales 2024 * | 3.98 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.82 x |
P/E ratio 2024 * |
-2.26
x | P/E ratio 2025 * |
-2.62
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.9% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | -3.02% | ||
1 week | -6.82% | ||
Current month | -8.04% | ||
1 month | -22.77% | ||
3 months | +2.23% | ||
6 months | +43.58% | ||
Current year | +34.28% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 12.76 | -2.60% | 160 469 |
24-05-07 | 13.1 | -10.27% | 264,668 |
24-05-06 | 14.6 | -3.76% | 116,822 |
24-05-03 | 15.17 | +9.06% | 124,535 |
24-05-02 | 13.91 | +2.58% | 116,755 |
Delayed Quote Nasdaq, May 08, 2024 at 11:44 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.28% | 277M | |
+23.02% | 46.4B | |
-1.59% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.05% | 26.01B | |
-19.10% | 19.52B | |
+30.56% | 12.43B | |
-0.17% | 12.18B | |
-0.60% | 12.13B |
- Stock Market
- Equities
- ENTA Stock